Temporal changes in mortality and risk factors of candidemia in intensive care unit patients.

Temporal changes in mortality and risk factors of candidemia in intensive care unit patients.

Publication date: Jun 06, 2026

Candida species are major causes of hospital-acquired bloodstream infections associated with high mortality in critically ill patients. This study aimed to evaluate temporal changes in species distribution, antifungal resistance, clinical outcomes, and mortality predictors in ICU patients with candidemia. This retrospective study included 250 ICU patients with candidemia between January 2018 and January 2022. The study period was divided into two cohorts (2018-2020, n = 80; 2020-2022, n = 170). Clinical, laboratory, and microbiological characteristics were compared. Multivariable analysis was performed to identify independent predictors of mortality. The incidence density of candidemia significantly decreased from 4. 32 to 3. 10 per 1,000 ICU patient-days (IRR: 0. 72; %95 CI: 0. 55-0. 94; p = 0,014). A shift toward non-albicans Candida species was observed, while antifungal resistance rates remained stable. Candida score values and empirical antifungal therapy rates were lower in the later period. Despite increased central venous catheter use, catheter-related candidemia decreased. Overall mortality was similar between periods; however, during the second period, mortality was higher in patients with SARS-CoV-2 infection than in those without infection [100/105 (95. 2%) vs. 43/65 (66. 2%), p 

Open Access PDF

Concepts Keywords
Candidemia Antifungal resistance
Laboratory Candidemia
Mortality Intensive care unit
Mortality
Non-albicans Candida

Semantics

Type Source Name
disease MESH candidemia
disease MESH bloodstream infections
disease MESH critically ill
disease MESH included
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease MESH Infectious Diseases
disease MESH Dis
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
drug DRUGBANK Urea
disease MESH Candida infection
disease MESH Severe Acute Respiratory Syndrome
disease MESH invasive candidiasis
disease MESH secondary infections
disease MESH malignancy
disease MESH diabetes mellitus
drug DRUGBANK Creatinine
disease MESH IBM
disease MESH pneumonia
disease MESH respiratory failure
drug DRUGBANK Oxygen
disease MESH clinical deterioration
disease MESH wound
disease MESH Hypertension
disease MESH Heart failure

Original Article

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *